Subscribe Become an Author Add Company Sign Up Log In

NuMedii

NuMedii

Private company
NUMEDII

NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of human, biological, pharmacological and clinical data points that the company has normalized and annotated. The company integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases.


Founded
2008
Status
Private company
Geography
United States of America based
Funding
$5.500 M
Patents
1
Research papers
14
Business model
  • Operations Service
Therapeutic focus
  • Rare Diseases
Data type used for modelling
  • EHRs/lab notebooks/databases (structured data mining)
  • Network biology analysis (omics)
  • Publications / patents (unstructured data mining)
Product type
  • Small molecules
Research focus
  • Biology research (Target identification/validation)
  • Drug Repurposing

Investing history

2015Series A2.0
2013Series A3.5

Press releases

    No mentions found

Posts Mentioning This Company

Biopharma Insights
Biopharma Insights

Products

No products posted yet

Services

No services posted yet

Clinical Trials

    No clinical trials found

Patents/applications
  • WO2014165823 (from 2014-10-09), Nadolol formulations for use in the treatment of inflammatory bowel disorders
Publications (PubMed)

    No publications found

Assets (therapeutic products)

    No assets found

Year Partner Focus Amount of Deal
2016

(2016, Jan. 1)
Astellas Drug Repurposing --
2017

(2017, Jan. 1)
Aptalis discover and develop new methods of treatment for certain gastrointestinal disorders and cystic fibrosis --